Compare ULTA & VTRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ULTA | VTRS |
|---|---|---|
| Founded | 1990 | 1961 |
| Country | United States | United States |
| Employees | N/A | 30000 |
| Industry | Other Specialty Stores | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 23.2B | 18.7B |
| IPO Year | 2007 | 2019 |
| Metric | ULTA | VTRS |
|---|---|---|
| Price | $546.14 | $17.92 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 23 | 4 |
| Target Price | ★ $663.95 | $13.50 |
| AVG Volume (30 Days) | 583.9K | ★ 6.9M |
| Earning Date | 05-28-2026 | 05-07-2026 |
| Dividend Yield | N/A | ★ 3.21% |
| EPS Growth | ★ 1.18 | N/A |
| EPS | ★ 14.31 | 0.05 |
| Revenue | $12,392,820,000.00 | ★ $14,299,900,000.00 |
| Revenue This Year | $9.31 | $4.41 |
| Revenue Next Year | $5.11 | $1.96 |
| P/E Ratio | ★ $38.35 | $348.40 |
| Revenue Growth | ★ 9.71 | N/A |
| 52 Week Low | $443.60 | $9.47 |
| 52 Week High | $714.97 | $18.39 |
| Indicator | ULTA | VTRS |
|---|---|---|
| Relative Strength Index (RSI) | 52.94 | 69.97 |
| Support Level | $502.10 | $15.94 |
| Resistance Level | $571.27 | $18.23 |
| Average True Range (ATR) | 14.14 | 0.38 |
| MACD | -1.12 | 0.11 |
| Stochastic Oscillator | 47.18 | 99.45 |
Ulta Beauty is the largest specialized beauty retailer in the US with more than 1,500 stores and e-commerce. The firm offers cosmetics (38% of 2025 sales), fragrances (13%), skin care (24%), and hair care products (19%). It also has salon services, including hair, makeup, skin, and brow, that account for 4% of its revenue and drive customer traffic. Outside of the US, Ulta operates premium beauty retailer Space NK (86 stores at year-end 2025 in the UK and Ireland), has franchised stores in Mexico, and a joint venture in the Middle East. Ulta was founded in 1990 and is based in Bolingbrook, Illinois.
Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of Viatris' total sales. The remaining 60% of sales are derived from its portfolio of legacy products, which includes Lipitor, Norvasc, Lyrica, and Viagra. While it covers more than 10 major therapeutic areas, Viatris has identified dermatology, ophthalmology, and gastroenterology as its three key areas of focus for future innovations.